|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-2, interleukin-4, interleukin-6, and transforming growth factor-beta have been implicated as cytokines that may be involved in the pathogenesis of systemic sclerosis.
|
1457282 |
1992 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The constitutive secretion of IL-6 may play an important role in the perpetuation of the local immune dysregulation and fibroblast activation in the SSc lesion.
|
7948613 |
1994 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Reverse transcriptase-polymerase chain reaction revealed that conditioned medium derived from both patients with SSc and controls induced mRNA expression of several fibrogenic cytokines such as IL-6, TNF-alpha, TGF-beta, and PDGF.
|
10090171 |
1999 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that endogenous IL-1alpha expressed by SSc fibroblasts may play a key role in the abnormal function of SSc fibroblasts through the expression of IL-6 and PDGF-A.
|
10225968 |
1999 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 (IL-6) is an important immunoregulatory cytokine that has been implicated in a number of fibrotic autoimmune diseases such as scleroderma, interstitial nephritis, and pulmonary interstitial fibrosis.
|
10720455 |
2000 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts.
|
11237429 |
2001 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Only IgG from SSc sera that were positive for antifibroblast antibody (AFA) induced a dose-dependent up-regulation of ICAM-1 expression and IL-6 production, enhancement of U937 cell adhesion, and increased levels of IL-1alpha, IL-1beta, and IL-6 mRNA in fibroblasts.
|
12115192 |
2002 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aberrant production of precursor IL-1alpha (pre-IL-1alpha) in skin fibroblasts that are derived from systemic sclerosis (SSc) is associated with the induction of IL-6 and procollagen, which contributes to the fibrosis of SSc.
|
16971486 |
2006 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study is to investigate the possible influence of -597 (-174) IL-6pr polymorphism on the susceptibility and/or the clinical course of SSc in Romanian population.
|
17125598 |
2007 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 78 patients with SSc [diffuse SSc (dcSSc), n = 31; limited SSc, (lcSSc), n = 47] and 692 healthy blood donors were genotyped for the following polymorphisms: IL10 T-3575A, IL10 A-1082G, IL1B C-31T, IL1B C-511T, IL1A C-889T, IL1RN A9589T, IL2 T-384G, LTA T-91G, and IL6 G-174C.
|
17444587 |
2007 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The MDR analysis showed a significant epistatic interaction among the interleukin-2 (IL-2) G-330T, IL-6 C-174G, and interferon-gamma AUTR5644T SNPs and the IL-1 receptor Cpst1970T, IL-6 Ant565G, and IL-10 C-819T SNPs in lcSSc and dcSSc susceptibility, respectively.
|
18576303 |
2008 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SSc alveolar T lymphocytes expressed a cytokine profile suggestive of a mixed Th1/Th2 reaction, showing an increased frequency of mRNA for interleukin (IL)-10, IL-6 and interferon (IFN)γ, while IL-1β, IFNγ and tumour necrosis factor β were expressed in blood T lymphocytes in a higher percentage of patients with SSc than controls.
|
21535076 |
2011 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High IL-6 expression early in dcSSc appears to be associated with more severe skin involvement at 3 years and worse long-term survival than in those without elevated IL-6 levels.
|
22586157 |
2012 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to determine whether the genetic variant -174 IL-6 contributes to differences in the response to rituximab in patients with systemic autoimmune diseases, including systemic lupus erythematosus (SLE), inflammatory myopathies, anti-neutrophil cytoplasmic antibody-mediated vasculitis, systemic sclerosis, Sjöegren's syndrome, rheumatoid arthritis, and autoimmune hemolytic anemia.
|
22734797 |
2012 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate whether the functional genetic variants rs8192284 and rs2228044 previously associated with several autoimmune diseases, located within the IL-6 receptor (IL-6R) subunits IL6R and IL6ST genes, respectively, are involved in the susceptibility to SSc and/or its major clinical subphenotypes.
|
22742541 |
2012 |
|
Systemic Scleroderma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the IL6 allelic combination analyses, the GGC allelic combination rs2069827-rs1800795-rs2069840 showed an association with overall SSc (Bonferroni p = 0.016, OR 1.13, 95% CI 1.04-1.23).
|
23027890 |
2012 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the levels of IL-6 (mean ± SD 314.3 ± 317.8 pg/ml versus 6.10 ± 2.58 pg/ml; P = 0.0007) and TGFβ (mean ± SD 1,020 ± 569 pg/ml versus 163.8 ± 98.69 pg/ml; P = 0.001) secreted by B lymphocytes from patients with SSc were increased compared to healthy controls.
|
27992693 |
2017 |
|
Systemic Scleroderma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Fraction exhaled nitric oxide (FeNO) and exhaled carbon monoxide (eCO) measured in EB, together with pH, nitrite, nitrate and interleukin-6 levels measured in EBC were prospectively analyzed in 35 patients with SSc.
|
28038794 |
2017 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum levels of IL-1β, IL-12 and IL-6 in PSS patients were significantly lower than those in controls (P < 0.003), and these associations survived the Bonferroni correction (Pc < 0.018).
|
28384257 |
2017 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Levels of CCL2, IL-10, and IL-6 were measured in 171 patients with early SSc in the Canadian Scleroderma Research Group (CSRG) replication cohort.
|
28575534 |
2017 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the role of cytokine (interleukin-1β, interleukin-6) and connective tissue growth factor (CTGF) production, and extracellular signal-regulated kinases (ERK) activation in mediating P2X7R-dependent pro-fibrotic effects in SSc fibroblasts was evaluated.
|
28955239 |
2017 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tocilizumab is an IL-6 receptor antagonist established as safe and effective, primarily in rheumatoid arthritis, and has shown promise in scleroderma.
|
28956500 |
2019 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A possible role of IL-6 in the regulation of firoblast differentiation and stimulation of collagen synthesis has been suggested and in patients with systemic sclerosis (SSc) the treatment with tocilizumab (TCZ) was associated to improvement of skin thickness and joint motion.
|
28980909 |
2017 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was evidence of altered distribution of transitional B cell subsets, increased production of interleukin-6 (IL-6) and IL-8, and defective tolerance induction in SSc B cells.
|
29193892 |
2018 |
|
Systemic Scleroderma
|
0.100 |
Biomarker
|
disease |
BEFREE |
After stimulation, we observed a lower proportion of IL-10 and IL-6 producing B-cells in SSc.
|
29343447 |
2018 |